Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

NCT04503694 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer Stage II
Rectal Cancer Stage III

Interventions

DRUG: Nivolumab 10 MG/ML Intravenous Solution
DRUG: Regorafenib 30 MG Oral Tablet
RADIATION: Radiotherapy
PROCEDURE: Surgery
PROCEDURE: Non-operative Management

Sponsor

Jules Bordet Institute